Our research and development work in the therapeutic area of Fertility is aimed at helping infertile couples to conceive a child, delivering products for every phase of the reproductive cycle from ovulation to early pregnancy. With our innovative treatments and technologies, we want to help couples increase their chances of a successful pregnancy. In addition, it is our aim to continue making our products as patient-friendly as possible.
For example, we are developing a long-acting recombinant follicle-stimulating hormone (hyperglycosylated FSH), which would mean fewer injections for patients. We successfully completed the Phase II program in assisted reproduction (ART) and are ready to advance the compound to Phase III. Phase II studies to evaluate efficacy in inducing ovulation are still underway.
We terminated the development of anastrozole, an aromotase inhibitor for ovulation induction, in July 2008. Although Phase II dose finding studies were successfully completed, the substance did not show a promising profile to be advanced to Phase III when compared to clomiphene citrate, the standard treatment.
back
